The Role of Carriers in DPI Capsules

Choice of carrier can have a significant impact on the capsule filling process as well as the performance of the DPI formulation.

May 02, 2018 by Adeline Siew, PhD Pharmaceutical Technology, Volume 42, Issue 5, pg 30–33

Amorphous – state Characterization and Dissolution Behaviour of Efavirenz – Tocopheryl Polyethylene Glycol Succinate (TPGS)-1000 Solid Dispersions

Investigating the Effectiveness of Different Porous Nanoparticles as Drug Carriers for Retaining the Photostability of Pinosylvin Derivative

Engineering of Highly Drug Loaded, Free-Flowing Mini-Particles via Tangential Spray Fluid Bed Granulation

The use of capsules loaded into a dry powder inhaler (DPI) to deliver drugs to the lungs is a well-established method for the treatment of lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Developing a capsule formulation for inhalation, however, is not nearly the same as an orally administered capsule. For DPI capsules, powder properties not only affect the manufacturing process but also drug delivery to the lungs. Experts from DFE Pharma—Mohit Mehta, scientist; Gerald Hebbink, scientist; and Harry Peters, lactose inhalation specialist—spoke to Pharmaceutical Technology about the importance of carrier selection and how the capsule filling process can affect DPI performance.

Continue on Pharmaceutical Technology

excipients